This study presents an exome-wide association analysis linking pharmacogenetic variants to bleeding risk in patients treated with apixaban or rivaroxaban. Although no genome-wide significant variants were identified, several candidate signals emerged and warrant further investigation.
Dmitry A. Sychev, Anastasiia A. Buianova, Sherzod P. Abdullaev, Karin B. Mirzaev, Vera A. Belova, Anna O. Shmitko, Valery V. Cheranev, Oleg N. Suchalko, Lyudmila V. Fedina, Svetlana V. Batyukina, Natalia A. Shatalova, Pavel O. Bochkov, Sergey V. Glagolev, Denis V. Rebrikov, Dmitriy O. Korostin